The results of the clinical study by Radboudumc were published in the October 2021 issue of the Journal of Bronchology & Interventional Pulmonology: Volume 28 - Issue 4 [1].
Dr. Erik van der Heijden, Pulmonologist and Associate Professor of Interventional Pulmonary Diseases at Radboudumc, led the study: “Initially, we were at a diagnostic accuracy of 72%. By the end, we were able to perform a biopsy using navigation in almost 100% of cases, and in 90% we had enough tissue for the pathologist to make a diagnosis. The average total effective radiation dose per procedure was reduced by more than half, including an effective fluoroscopy radiation dose reduction from 5.2 mSv to 0.37 mSv.”
“My focus is on detecting lung cancer at an early stage. A tumor in the lungs is now often discovered by chance, because a CT scan is performed for a reason other than lung complaints and a suspicious spot is then found in the lungs by chance. From such a suspicious abnormality, you would then like to obtain tissue in a safe manner that a pathologist can use to make a diagnosis.”
We started researching ways to use CBCT technology, in this case Philips Lung Suite, to increase the accuracy of diagnosis while reducing the radiation dose.
Dr. Erik van der Heijden
Pulmonologist and Associate Professor of Interventional Pulmonary Diseases at Radboudumc
“You could say we have had a very steep learning curve,” comments Dr. Heijden. “That was due to a number of factors, but the 3D imaging capabilities of the cone-beam CT scanner helped to continually evaluate and perfect the navigation procedure. And we introduced new protocols, which allowed the search area to be made smaller, which in turn allows for lower radiation into the lungs. We actually started using the Philips Azurion platform more in the way it was made for. For example, we can now image patients with an overlay of augmented fluoroscopy. That took some practice, but in the end the results are great. We are currently the first in the world to have such a high yield with this technology.”
What helped, according to Dr. Heijden, was the collaboration with technical physician Roel Verhoeven. “Our team composition is really great in that respect. It really helps when someone with a solid technical background is on your side,” he says. “Besides that, it was just a matter of persevering, and gaining experience with the use of 3D imaging. Only if you keep innovating as a physician can you make the results for patients better and better.”
Dr. Heijden’s team worked closely with Philips in the study. "Because the application of this technology plays such a large role in successfully performing these procedures, it is important that we can spar with the team at Philips in an approachable way. Among other things, they helped us increase the accuracy and safety of the procedure by making the imaging more specific to the different requirements and phases of the procedure.”
In the future, Dr. Heijden hopes to increase the use of navigation technology to treat patients with lung cancer. “Patients sometimes say “if you're in the lungs during such a biopsy anyway, just get it [the lesion] out right away”. In the future, that will become possible using microwave ablation, where you can focus microwaves directly into the tumor. We haven't got that far yet, but it could be a very good alternative to radiation and chemotherapy. Then it does help if you can see very well, in real time, where you are in the lung using 3D imaging.”
[1] Journal of Bronchology & Interventional Pulmonology: October 2021 - Volume 28 - Issue 4 - p 262-271 doi: 10.1097/LBR.0000000000000783
By clicking on the link, you will be leaving the official Royal Philips Healthcare ("Philips") website. Any links to third-party websites that may appear on this site are provided only for your convenience and in no way represent any affiliation or endorsement of the information provided on those linked websites. Philips makes no representations or warranties of any kind with regard to any third-party websites or the information contained therein.
I understandYou are about to visit a Philips global content page
You are about to visit the Philips USA website.
Door op de link te klikken, verlaat u de officiële website van Royal Philips Healthcare ("Philips"). Alle links naar websites van derden die op deze site kunnen verschijnen, zijn alleen bedoeld voor uw gemak en vertegenwoordigen op geen enkele manier enige aansluiting bij of goedkeuring van de informatie die op die gelinkte websites wordt verstrekt. Philips geeft geen verklaringen of garanties van welke aard dan ook met betrekking tot websites van derden of de daarin opgenomen informatie.
Ik begrijp hetYou are about to visit a Philips global content page
You are about to visit the Philips USA website.
Select country
Global (English)By clicking on the link, you will be leaving the official Royal Philips Healthcare ("Philips") website. Any links to third-party websites that may appear on this site are provided only for your convenience and in no way represent any affiliation or endorsement of the information provided on those linked websites. Philips makes no representations or warranties of any kind with regard to any third-party websites or the information contained therein.
I understandYou are about to visit a Philips global content page
You are about to visit the Philips USA website.
Our site can best be viewed with the latest version of Microsoft Edge, Google Chrome or Firefox.